Fiche centre
UMC Utrecht
Utrecht — Netherlands
Essais liés10clinical trials
VilleUtrechtlocalisation
PaysNetherlandslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02710435
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Implant of investigational device system | Insuffisance cardiaque | Non applicable | NCT01385176 | Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF) | ACTIVE_NOT_RECRUITING |
| Pulsed Field Ablation | Maladie coronarienne | Non applicable | NCT06106594 | VOLT CE Mark Study | ACTIVE_NOT_RECRUITING |
| MIDCAB procedure | Maladie coronarienne | Non applicable | NCT07892976 | The CORE Platform Trial | NOT_YET_RECRUITING |
| Dapagliflozin 10 mg/day (oral) | Maladie rénale chronique | Phase 3 | NCT05374291 | The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | ACTIVE_NOT_RECRUITING |
| Empagliflozin | Maladie rénale chronique | Phase 3 | NCT07107945 | A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | ACTIVE_NOT_RECRUITING |
| Reducer System | Maladie coronarienne | À vérifier | NCT02710435 | REDUCER-I: An Observational Study of the Neovasc Reducer™ System | ACTIVE_NOT_RECRUITING |
| ARGX-119 | Sclérose latérale amyotrophique | Phase 2 | NCT06441682 | ReALiSe — A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | TERMINATED |
| Emapalumab | Lupus | Phase 3 | NCT05001737 | EMERALD — Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE | COMPLETED |
| VTx-002 | Sclérose latérale amyotrophique | Phase 1/2 | NCT07287397 | Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS | RECRUITING |
| Pridopidine | Sclérose latérale amyotrophique | Phase 3 | NCT07322003 | PREVAiLS — Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | RECRUITING |